SELLAS Life Sciences Group, Inc.
SLSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. Valued at $2.82B, SLS is a mid-cap name in its sector. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Cap
$2.82B
Beta
2.52
P/E (TTM)
—
P/E (Fwd)
-139.60
EPS (TTM)
$-0.22
EPS (Fwd)
$-0.10
ROE
-39.6%
ROA
-23.3%
Cash
$138.3M
Total Debt
$737,000
Free CF
-$16.4M
52W Change
637.2%
Annual Financials
Cash vs Debt
Where SLS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SLS finished 77.67% above its 150-day moving average ($7.97) and 111.98% above its 200-day moving average ($6.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLS overbought or oversold?
At the September 3, 2026 close, SLS's RSI(14) was 58.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SELLAS Life Sciences Group, Inc. holds $138.3M in cash against $737K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$16.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -39.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.0M (2022) to $0 (2025), a 100% decline worth watching.
SELLAS Life Sciences Group, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SLS.